Total Payments
$1,996
2024 Payments
$437.04
Companies
20
Transactions
42
Medicare Patients
898
Medicare Billing
$184,146
Payment Breakdown by Category
Food & Beverage$1,973 (98.8%)
Education$23.50 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,973 | 40 | 98.8% |
| Education | $23.50 | 2 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $479.11 | 11 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $255.43 | 3 | $0 (2022) |
| Genentech USA, Inc. | $213.69 | 2 | $0 (2017) |
| Exelixis Inc. | $174.00 | 1 | $0 (2024) |
| Immunocore Limited | $144.00 | 1 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $124.51 | 1 | $0 (2019) |
| PFIZER INC. | $120.89 | 2 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $119.04 | 1 | $0 (2024) |
| Lilly USA, LLC | $88.13 | 2 | $0 (2019) |
| Janssen Biotech, Inc. | $45.75 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $437.04 | 3 | Exelixis Inc. ($174.00) |
| 2023 | $104.24 | 1 | PFIZER INC. ($104.24) |
| 2022 | $135.72 | 2 | E.R. Squibb & Sons, L.L.C. ($124.87) |
| 2020 | $65.63 | 5 | Seagen Inc. ($28.42) |
| 2019 | $638.72 | 16 | Merck Sharp & Dohme Corporation ($346.05) |
| 2018 | $125.23 | 8 | Ipsen Biopharmaceuticals, Inc ($39.73) |
| 2017 | $489.54 | 7 | Genentech USA, Inc. ($213.69) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $119.04 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $144.00 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $174.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/08/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $104.24 | General |
| Category: ONCOLOGY | ||||||
| 05/04/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $124.87 | General |
| Category: Oncology | ||||||
| 01/06/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $10.85 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $12.65 | General |
| Category: Oncology | ||||||
| 05/19/2020 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2020 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Oncology | ||||||
| 01/31/2020 | Celgene Corporation | Revlimid (Drug), Pomalyst | Food and Beverage | Cash or cash equivalent | $11.80 | General |
| Category: Hematology | ||||||
| 01/03/2020 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Oncology | ||||||
| 11/08/2019 | Merck Sharp & Dohme Corporation | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: Oncology | ||||||
| 09/18/2019 | Sun Pharmaceutical Industries Inc. | ODOMZO (Drug) | Food and Beverage | Cash or cash equivalent | $124.51 | General |
| Category: Oncology | ||||||
| 07/26/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $11.36 | General |
| Category: Oncology | ||||||
| 06/07/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/31/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 05/24/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Oncology | ||||||
| 04/24/2019 | Lilly USA, LLC | ERBITUX (Drug) | Food and Beverage | In-kind items and services | $73.44 | General |
| Category: Oncology | ||||||
| 04/24/2019 | Lilly USA, LLC | ERBITUX (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Oncology | ||||||
| 03/08/2019 | Merck Sharp & Dohme Corporation | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $8.97 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2019 | Array BioPharma Inc. | Braftovi (Drug), Mektovi | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: Melanoma | ||||||
| 02/22/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Oncology | ||||||
| 02/08/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $31.99 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 204 | 454 | $150,367 | $37,063 |
| 2022 | 4 | 192 | 510 | $164,952 | $41,911 |
| 2021 | 6 | 264 | 639 | $199,743 | $53,725 |
| 2020 | 6 | 238 | 708 | $217,306 | $51,447 |
Total Patients
898
Total Services
2,311
Medicare Billing
$184,146
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 127 | 338 | $101,062 | $26,535 | 26.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 47 | $18,753 | $4,763 | 25.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 19 | 28 | $13,860 | $2,158 | 15.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $9,240 | $1,818 | 19.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 27 | $7,452 | $1,789 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 146 | 444 | $132,756 | $35,442 | 26.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 29 | $11,571 | $2,547 | 22.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 14 | 14 | $9,240 | $2,061 | 22.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 14 | 23 | $11,385 | $1,861 | 16.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 151 | 494 | $147,706 | $41,062 | 27.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 37 | $14,763 | $3,330 | 22.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 39 | 50 | $9,650 | $2,923 | 30.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 26 | 33 | $12,960 | $2,921 | 22.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $8,580 | $2,149 | 25.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $6,084 | $1,340 | 22.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 161 | 629 | $188,071 | $43,910 | 23.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 28 | 28 | $18,480 | $4,261 | 23.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 11 | $4,719 | $1,088 | 23.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 13 | 14 | $1,680 | $984.24 | 58.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 14 | 14 | $2,040 | $650.16 | 31.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 11 | 12 | $2,316 | $553.56 | 23.9% |
About Dr. Lynn Feun, MD
Dr. Lynn Feun, MD is a Internal Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902832520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lynn Feun, MD has received a total of $1,996 in payments from pharmaceutical and medical device companies, with $437.04 received in 2024. These payments were reported across 42 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,973).
As a Medicare-enrolled provider, Feun has provided services to 898 Medicare beneficiaries, totaling 2,311 services with total Medicare billing of $184,146. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Miami, FL
- Active Since 06/24/2006
- Last Updated 11/04/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1902832520
Products in Payments
- OPDIVO (Biological) $255.43
- LENVIMA (Drug) $193.99
- CABOMETYX (Drug) $174.00
- KIMMTRAK (Drug) $144.00
- ODOMZO (Drug) $124.51
- KEYTRUDA (Biological) $121.30
- LIBTAYO (Biological) $119.04
- Erivedge (Biological) $113.69
- BRAFTOVI (Drug) $104.24
- Zelboraf (Biological) $100.00
- ERBITUX (Drug) $88.13
- ADCETRIS (Biological) $56.40
- Somatuline Depot (Drug) $39.73
- YONDELIS (Drug) $29.63
- LYNPARZA (Biological) $27.07
- IMFINZI (Drug) $25.90
- SANDOSTATIN LAR (Drug) $20.06
- INLYTA (Drug) $16.65
- ZYTIGA (Drug) $16.12
- CALQUENCE (Drug) $13.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Miami
Jay Skyler, Md, MD
Internal Medicine — Payments: $2.9M
Internal Medicine $2.9M
Dr. Lukasz Kwapisz
Internal Medicine — Payments: $800,664
Internal Medicine $800,664
Mark Kutner, Md, MD
Internal Medicine — Payments: $610,516
Internal Medicine $610,516
Dr. Ian Del Conde Pozzi, M.d, M.D
Internal Medicine — Payments: $499,756
Internal Medicine $499,756
Mr. Angel Carrasco, M.d, M.D
Internal Medicine — Payments: $493,362
Internal Medicine $493,362
Dr. Edward Mezerhane, Md, MD
Internal Medicine — Payments: $470,504
Internal Medicine $470,504